Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) has been given a consensus rating of “Hold” by the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $17.17.
Several research analysts recently weighed in on the company. BidaskClub upgraded Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, April 17th. ValuEngine raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 1st. Cantor Fitzgerald set a $18.00 price objective on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 9th. Finally, Wells Fargo & Co raised Bellicum Pharmaceuticals from a “market perform” rating to an “outperform” rating and lowered their price objective for the stock from $8.30 to $6.85 in a research note on Wednesday, April 11th.
Shares of BLCM traded down $0.10 during mid-day trading on Tuesday, hitting $5.87. 292,627 shares of the stock were exchanged, compared to its average volume of 499,675. Bellicum Pharmaceuticals has a 52-week low of $5.02 and a 52-week high of $13.30. The company has a quick ratio of 6.75, a current ratio of 6.75 and a debt-to-equity ratio of 0.53.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.02. The business had revenue of $0.15 million during the quarter, compared to analysts’ expectations of $0.08 million. research analysts predict that Bellicum Pharmaceuticals will post -2.35 EPS for the current fiscal year.
In other Bellicum Pharmaceuticals news, insider David M. Spencer sold 40,000 shares of Bellicum Pharmaceuticals stock in a transaction on Wednesday, July 18th. The stock was sold at an average price of $7.63, for a total value of $305,200.00. Following the sale, the insider now owns 99,939 shares in the company, valued at $762,534.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Alan A. Musso sold 6,206 shares of Bellicum Pharmaceuticals stock in a transaction on Friday, May 25th. The shares were sold at an average price of $7.97, for a total value of $49,461.82. Following the completion of the sale, the chief financial officer now owns 26,548 shares in the company, valued at approximately $211,587.56. The disclosure for this sale can be found here. Insiders own 9.84% of the company’s stock.
A number of large investors have recently bought and sold shares of BLCM. Knott David M raised its holdings in shares of Bellicum Pharmaceuticals by 12.8% in the 1st quarter. Knott David M now owns 67,653 shares of the biopharmaceutical company’s stock valued at $444,000 after buying an additional 7,669 shares during the period. Principal Financial Group Inc. boosted its position in shares of Bellicum Pharmaceuticals by 95.2% during the 1st quarter. Principal Financial Group Inc. now owns 160,100 shares of the biopharmaceutical company’s stock worth $1,050,000 after acquiring an additional 78,070 shares in the last quarter. Commonwealth Equity Services LLC boosted its position in shares of Bellicum Pharmaceuticals by 52.8% during the 1st quarter. Commonwealth Equity Services LLC now owns 18,888 shares of the biopharmaceutical company’s stock worth $123,000 after acquiring an additional 6,530 shares in the last quarter. Millennium Management LLC boosted its position in shares of Bellicum Pharmaceuticals by 97.9% during the 1st quarter. Millennium Management LLC now owns 245,868 shares of the biopharmaceutical company’s stock worth $1,613,000 after acquiring an additional 121,608 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Bellicum Pharmaceuticals by 22.4% during the 1st quarter. JPMorgan Chase & Co. now owns 2,863,044 shares of the biopharmaceutical company’s stock worth $18,782,000 after acquiring an additional 523,976 shares in the last quarter. Institutional investors own 43.01% of the company’s stock.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Further Reading: Market Capitalization and Individual Investors
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.